Yu C, Niu L, Li L, et al. - The current study demonstrated the metabolic features of prostate cancer (PCa), providing strong evidence that the amide nitrogen and energy metabolic pathways could be a valuable source of PCa markers. Several candidate markers identified in this study were clinically significant and warranted further investigation.

• Using LC-MS/MS and GC-MS, plasma and urine metabolites from 89 PCa patients, 84 benign prostatic hyperplasia (BPH) patients, and 70 healthy males were analyzed.

• A series of altered metabolites related to the urea cycle, tricarboxylic acid cycle, fatty acid metabolism, and the glycine cleavage system were discovered using multivariate statistical analyses.

• When it came to distinguishing PCa patients from healthy controls, plasma Glu/Gln had a higher sensitivity than PSA.

• When separating PCa patients from BPH patients, both Glu/Gln and PSA had a low specificity (< 53.2%), but the combination of Glu/Gln and PSA can increase the diagnostic specificity to 66.9%.